ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease
The ESMO Congress 2025 has seen pivotal studies unveiling compelling evidence that a new class of…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer
Results from a trial presented at ESMO 205 have shown that a targeted therapy combination improved…
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms
A multicenter Phase II clinical trial has demonstrated significant tumour shrinkage and disease control in patients…
ESMO 2025: Novel treatment combination improves progression-free survival in metastatic, oestrogen-receptor-positive HER-2-negative breast cancer
Patients with oestrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with…
New imaging solution could help improve survival for patients with recurring prostate cancer
A multicentre study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute…
ESMO 2025: Chemo combination boosts overall survival in patients with EGFR-mutant NSCLC
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful…
From molecular pathways to potential treatments: Targeting epithelial‒mesenchymal transition in glioblastoma
Glioblastoma (GBM), a malignant tumour originating from glial cells, is the most common primary tumour…
ESMO 2025: Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
A drug that harnesses the immune system to attack cancer cells has proved successful in…
New research helps model how the immune system shapes cancer development
Understanding the interaction between immune cells and cancer cells has significant implications for cancer immunotherapies,…
Velcro-like pan-cancer immunotherapy destroys tumours
A new, highly potent class of immunotherapeutics with unique Velcro-like binding properties can kill diverse…